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Objectives: Many initiatives (e.g., PROTECT, EFSPI) are exploring quantitative meth-
odologies to conduct benefit/risk assessments of medicines. Objectives of this study 
were to combine quantitative methodologies that can capture expert knowledge 
and decisionmakers insights to genuinely support real-world decisions. MethOds: 
Using the case study of efalizumab, approved by the EMA in 2004 for the treatment 
of plaque psoriasis and withdrawn in 2009, a pragmatic methodology was developed 
that combines advanced pharmacoepidemiology and MCDA for quantitative benefit/
risk assessment. Development involved application of: MCDA principles to ensure 
applicability to any therapeutic area, comparability across medicines, and portabil-
ity over product cycle (re-evaluation); and advanced pharmacoepidemiology and 
Bayesian modeling to identify/generate most useful data. Overarching design was 
guided by ethical implications of criteria and data selection as well as applicability in 
real life settings including face validity, time constraints, complexity and transpar-
ency. Results: The hierarchical multicriteria model consists of two major domains: 
Benefits (favourable effects, covering the criteria Clinical efficacy/effectiveness and 
Patient Reported outcomes); and Risks (unfavourable effects – criterion Safety). The 
safety criterion is subdivided into three generic subcriteria (Adverse events, Serious 
AEs and Fatal AEs). The benefit criteria are subdivided into specific subcriteria that 
correspond to the most relevant outcomes for a treatment for plaque psoriasis. All 
performance are assigned relative to existing alternatives or placebo. Each subcri-
terion contributes to the output of the model, the Benefit/Risk Estimate, which is 
the sum of normalized weights for each subcriterion multiplied by the respective 
performance score. Pharmacoepidemiology data is provided in a standardized for-
mat for each subcriterion and includes meta-analytic comparative statistics based 
on clinical trials, observational data and Bayesian models. Uncertainty is explored 
in sensitivity analyses. cOnclusiOns: Integration of pragmatic MCDA modeling 
with advanced pharmacoepidemiology allows quantitative benefit/risk assessment 
that can be applicable and meaningful in real life regulatory settings.
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Objectives: The Center for Translational Molecular Medicine (CTMM) is a multi-
million public-private partnership, including universities, academic hospitals, phar-
maceutical and medical technology companies. CTMM aims to accelerate molecular 
diagnostics and imaging technologies to enable determination of predisposition, 
early diagnosis, and personalized treatment of patients. It is unique in that it man-
dates early Health Technology Assessment (HTA) in each of its 21 projects. This study 
assessed the impact of CTMM on scientific, translational, clinical and economic 
aspects. MethOds: The impact assessment was guided by the “Research Impact 
Framework” (Kuruvilla 2006) Objective data were gathered from extensive CTMM 
administrations, including publications, patents, project proceedings, early HTA 
results, etc. Perceived impact was investigated using a CTMM-wide survey (n= 167) 
and two focus groups. Results: CTMM focuses its impact on disease areas with 
high Disability Adjusted Life Years and high societal costs, i.e. oncology, cardiovas-
cular, neurologic, infection and immunity diseases. Its scientific impact is as high 
as the overall impact of Dutch biomedical research, i.e. 15%-80% above international 
volume and journal impact standards. CTMM is perceived to stimulate and acceler-
ate translation of technology to the clinic, with a median score of 4 out of 5 (IQR 
3-5). Its main strength lies in pre-clinical and phase 1 development (median score 
4 of 5; IQR 4-5). CTMM has generated nearly 1900 FTE of translational R&D capacity 
between 2008-15. Experience with and impact of early HTA varies widely between 
projects (median score 3 of 5; IQR: 2-4). CONCLUSION: By facilitating and managing 
effective and safe public-private collaboration, CTMM has demonstrated a solid sci-
entific impact. Its impact on translational, (future) clinical and economic aspects is 
generally perceived as large. Metrics to objectively measure this need improvement 
as well as longer follow-up. The early HTA analyses have provided critical insights 
and exemplar approaches for future early HTA work in public-private partnerships.
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Objectives: In 2011 was published 12.401 Law establishing the National Committee 
for Technologies Incorporation in SUS (CONITEC) and defining the criteria and dead-
lines for the analysis and adoption of technologies. According to the law, CONITEC’s 
assessment must considers necessarily scientific evidences about efficacy, accuracy, 
effectiveness and safety of technologies and economic evaluation studies of ben-
efits and costs in relation to the technologies already incorporated in SUS. Studies 
of economic evaluation traditionally ignore equity in health, and because this gap, 
researches have been undertaken to develop methods to incorporate equity into 
economic evaluation in health. Thus, this paper aims to analyze the viability of 
using an economic evaluation framework in the decision making process about 
incorporating technologies so that the equity is maximized within the Brazilian 
Unified Health System. MethOds: To fulfill this goal, review the scientific lit-
erature for methods to incorporate equity into cost-effectiveness was conducted 
with subsequent discussion how the methods found can be applied in the con-
text of SUS, a system that offers universal coverage to approximately 201 million 
citizens. Results: Until end of 2013, CONITEC recommended the incorporation of 
64 technologies for diagnosis, prevention and treatment of various diseases, and 
no study of economic evaluation submitted addressed the issue of equity. By the 
research found a systematic review conducted by Johri & Norheim (2012) having 
found three distinct approaches: integration of distributional concerns through 
equity weights and social welfare functions, exploration of the opportunity costs 
of alternative policy options, through mathematical programming and multi-cri-
aspect of the pharmaceutical industry. After the reform policy in 1978, both the 
governmental regulators and the regulated pharmaceutical industry became devel-
opment-oriented. The effective control of the quality and safety of pharmaceutical 
products became a serious problem. In order to reverse the situation China tried 
to establish an independent drug regulatory system. cOnclusiOns: Because of 
path dependence it is very difficult to turn the drug regulatory system from the sys-
tem of unification of the regulators and the regulated into an independent system. 
The introduction of a formally independent regulatory system has improved the 
regulator’s motive to supervise the quality and safety of drugs to some extent. But 
many impediment factors still exist both inside and outside China’s drug regula-
tory system. The great difficulties to establish an effective drug regulatory system 
China experienced during the past 10 years proved that the old way in which the 
government regulatory agencies operate is very difficult to shake. The policy maker 
should fully understand the impact of the previous system and make a long and 
Coordinative effort. The best way to establish a good independent drug regulatory 
system has to be a gradual rather than a radical reform.
PHP123
PersPecTive Of sOciAl PArTiciPATiOn in THe evAluATiOn PrOcess Of 
incOrPOrATing TecHnOlOgy in HeAlTH cAre
Chacarolli CFT, Silveira L.C., Rabelo R., Gonçalves H., Vidal J.R., Gandara P.M., Biella C.,  
Santos V.C.C., Petramale C.
Brazilian Ministry of Health, Brasília-DF, Brazil
Objectives: The Brazilian Public Health System (SUS) was established in 1988, 
thereby ensuring that the citizen universal right to health, having as one of its 
principles to the participation or social control. The performance of the SUS in the 
field of evaluation and incorporation of new technologies represents the public 
interest as defined by universal policies are committed to the equity and based on 
scientific knowledge consistent. The year of 2011 represented a breakthrough in 
transparency and social participation in the process of incorporating technology 
with the publication of Law no. 12,401, of 28/04/2011, which has set up a National 
Commission for the Incorporation of Technology in the SUS/CONITEC. The aim of 
this study was to identify in the participation of public consultations of CONITEC, 
the civil society participation, public and private institutions. MethOds: This is a 
descriptive, cross-sectional study, which was developed from the analysis of tech-
nical reports of Conitec which related to public consultation by the committee 
were extracted data to support decision-making on technology incorporation in 
SUS. Results: In the years 2012 and 2013, 78 public consultations and more than 
4,182 contributions were examined by CONITEC published arising from health care 
institutions, patient association, educational institutions, medical societies, etc, that 
recommended to incorporate 64 new technologies in the SUS. cOnclusiOns: The 
Ministry of Health, responsible for enforcement of the law n. 12.401, use system-
atically the public consultations as the instrument to gather contributions from 
segments of society in their process work. To the extent that such participation 
is intended to subsidize the decision about incorporating technology in the SUS, 
there are significant gains in building the public policy agenda, adding legitimacy 
and transparency in government decision-making.
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Objectives: The Brazilian public health system ensures universal, equitable and 
comprehensive access to health technologies, including medicines. The high-cost 
medicines are offered through Specialized Pharmaceutical Services Component 
(SPSC). The clinical conditions treated in the SPSC are defined in the Guidelines in 
the form of lines of care. To describe the experience and results of the SPSC with its 
particular strategies in the quest for the comprehensive health care. MethOds: 
Focused on the SPSC’s issues, we did a retrospective data analysis related to its 
management strategies for the pharmaceutical services in the public health sys-
tem in the period 2010 to 2013. Data were obtained from documents of the Ministry 
of Health in 2013 (current values; exchange rate: US$ 1 = R$ 2.30). Results: As 
a strategy to increase medicines access and optimization of resource allocation, 
the MoH expanded the amount of centralized procurement medicines, from 13 
to 51 products. This deed was focused on those medicines with a concentrated 
market. As a consequence, this action allowed a saving of U$ 403.8 million in four 
years, compared to the price in 2010. The medicines that most contributed to the 
economy were adalimumabe (U$120 million), etanercepte (U$100 million) and 
infliximab (U$44 million). Betainterferona (52%), etanercepte (48%), imiglucerase 
(48%), adalimumabe (37%) e Alfapeginterferona (37%) were the products with a 
greater reduction in the unit price, considering the accumulated value at period. 
The increase in the number of units distributed was 263%. cOnclusiOns: The 
SPSC was designed in 2010 for the budgetary resources optimization and to expand 
access to medicines for diseases that require complex health services or high-cost 
medicines. The purchasing power of the MoH is a strategy that allowed expansion 
of access to medicines, with optimization of budgetary resources in the Brazilian 
public health system.
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that the launch of the NHI system. To improve the system even further, future chal-
lenge will be our motive to reform and also lead us to a new stage in health care.
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Glioblastoma (GBM) is an aggressive, high-grade glioma characterized by rapid 
growth and microvascular proliferation. Tumors are typically localized to the cer-
ebrum and rarely distantly metastasize. Worsening of neurocognitive symptoms is 
observed with GBM progression, and can significantly impact patient function and 
quality of life. Current treatments are non-curative and have not demonstrated 
an increase in overall survival. Progression-free survival (PFS) is a common pri-
mary endpoint in clinical trials of GBM therapies; however, it is important in this 
patient population to quantify how time without disease progression benefits 
patients. Recent decisions by health authorities and payers suggest an increasing 
trend towards the need for evidence of patient-centered endpoints, particularly for 
reimbursement decision-making. Assessment of neurocognitive deterioration due 
to GBM progression during the clinical trial period is challenging given the need to 
sensitively assess a range of symptoms that may manifest due to lesions in differ-
ent regions of the brain. A disease model, or conceptual framework, is needed to 
ground decision-making around choice of instruments, endpoints, and schedules 
of symptom assessments, thus ensuring measurement of the most patient and bio-
logically relevant symptoms. The framework presented here outlines the biological 
processes that contribute to non-focal symptoms of GBM, such as headache, as well 
as focal symptoms, such as visual disturbances, changes in memory, or loss of verbal 
expression. Considerations and challenges in assessing neurocognitive symptoms in 
GBM patients utilizing existing tools and methodologies are reviewed and identified.
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Developed countries have largely achieved universal health care coverage, while 
many developing countries are implementing steps to increase health care cover-
age. While the objective is the same, the health care systems and policies across 
countries differ across countries leading to different levels of access to medicines. 
To understand which systems and policies can lead to better access, we need a 
measure to evaluate how well countries do in terms of providing access to medi-
cine for their populations. In this paper, we develop a Country Access to Medicines 
Index that compares and ranks countries on access to medicine outcomes. This 
index is based on five pillars – ease of accessibility to health care workers and 
facilities, awareness of disease diagnosis and treatment, availability of medicines, 
affordability of medicines and adherence to right treatment. We identify key vari-
ables in each of these pillars and compare and rank 30 countries with more than 
60% of the world’s population on each of these variables, at an aggregate level 
on each pillar, and overall. We draw upon IMS data as well as international and 
country level sources to obtain the data needed for the measures. We then look at 
the health systems and policies in these countries to identify features that lead to 
better performance on the index. We find that five broad factors can help explain 
access to medicines performance. First is the level of financing of health care, espe-
cially reimbursement coverage. Second is a structured and transparent pricing and 
patient access system that prioritises resource allocation to high need diseases and 
patients and sets economically justifiable prices. Third is the level of development 
of health care infrastructure. Fourth, is the provider and pharmacy incentives that 
promote appropriate use of medicine. And finally, a system that ensures the proper 
implementation of health policy initiatives.
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The increasing adoption of Internet and social media have facilitated the emergence 
of patient opinion leaders (POLs). These influential individuals are living with a 
chronic disease and are writing about their experiences on Internet blogs and social 
media websites. Popular and highly-trusted patients are labeled as POLs because 
their work influences the decision-making of other patients. Top POLs have tens 
of thousands of followers who subscribe to their websites, blogs, and online social 
media accounts. POLs usually focus on one therapeutic area and provide disease-
related information, treatment options, and emotional support to other patients. 
Additionally, some POLs are health activists who help shape health policy and 
provide input into clinical trial design including endpoint development. As health 
care increases its focus to center around the individual patient, pharmaceutical 
companies and government agencies will seek out POLs for their personal perspec-
tives. A formal methodology to measure the influence and reach of POLs has yet 
to be established. Their influence on the Internet can be determined by the size of 
their audience (e.g., Twitter followers), relevancy of posted content to the disease 
state of interest, frequency of posted content, and perceived trustworthiness based 
on various scales (e.g., Google’s PageRank algorithm). By characterizing and index-
ing POLs, interested stakeholders can easily engage with them to incorporate the 
patient’s voice into clinical trials, market research, health policy, and marketing. As 
an example, researchers can capture and leverage the large audience of an influen-
tial POL to recruit patients for a clinical trial or to garner feedback on the endpoints 
of a clinical trial from the patients’ perspectives. This paper’s objective is to evaluate 
teria decision analysis. cOnclusiOns: These and other methods may be used by 
CONITEC’s assessment, approaching the issues of efficiency and equity in decision 
making. Thus, is expected to contribute to the development and application of these 
decision-support tools and to improve the criteria of Ministry of Health for deciding 
which technologies to fund.
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Objectives: An application of predictive and pharmacogenetic tests in appoint-
ment of targeted anti-cancer therapy and predict response to treatment. Considering 
significant practical necessity of molecular-genetic methods for health care and 
high cost, it is important to evaluate these technologies in terms of health econom-
ics. MethOds: A systematic review of articles has been conducted using databases 
PubMed, The Cochrane Library, and published reports and market reviews. Results: 
In the period from 2007 to 2012 it is estimated the world market in vitro diagnostic 
(IVD) is increasing due to the development of molecular diagnostic tests and rapid 
test kits. Experts point out that a key factor in the growth segment of molecu-
lar diagnostics in recent years has been precisely the emergence of new oncology 
tests to prescribe targeted therapy. At the moment, in IVD diagnostics segment in 
Russia market is forecasted growth rate for 2014 at 10-20%. Price of tests for oncol-
ogy biomarkers depends on the technology: - for most routine immunological and 
chemical tests is between 10 and 15 USD; - for molecular genetic tests costs varies 
from 40 to 4000 USD per procedure. In addition to practiced in Russian Federation 
KRAS- and EGFR-testing, in this review discussed the practical value of: testing 
EML4-ALK mutation for crizotinib in non-small lung cancer; BRAF V600E-testing 
for vemurafenib in melanoma; HER2/neu-testing for trastuzumab in breast cancer. 
Thus, the Russian segment of the cancer diagnostics market is the fast-growing 
market. However, the analysis of the literature showed that until that time in the 
Russian Federation was not conducted clinical and economic evaluation of these 
medical technologies. cOnclusiOns: The analysis revealed that evaluation of diag-
nostic test systems in oncology from the point of view of health economics of the 
Russian Federation is a topical field for research and requires a rigorous analysis.
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Transitional care management programs have been shown to improve medication 
adherence, elevate patient comprehension of their disease state, increase patient 
satisfaction, and reduce preventable readmission rates due to certain diagno-
ses (e.g., congestive heart failure). However, the true value of such programs has 
recently become more important to key health care decision makers as the United 
States transitions away from a fee for service model to a value based payment 
system. The provision of medication therapy management is a vital component 
of many transitional care management programs, yet the cost effectiveness of 
pharmacist interventions remains difficult to quantify. The inability to assign 
a universally accepted economic value to such transitional care programs has 
hindered the implementation of a sustainable business model for such services; 
despite the positive impact on patient health outcomes. This paper explores the 
unique challenges a national post-acute health care network faced while attempt-
ing to incorporate cost-effective clinical pharmacy services into its transitional 
care management programs. First, we discuss the impact of various strategies to 
stratify patient readmission risk in different settings of care. Second, the challenge 
to participate in a risk-sharing model in a health system still driven by patient 
choice is investigated. Finally, we evaluate the published methods used to quantify 
the economic impact clinical pharmacist interventions. Our assessment of the 
above topics is applied to three case studies; each located in a distinct region of 
the United States and with unique approaches to the provision and reimburse-
ment of health care. Our conclusions support the need for additional investment 
into the value of transitional care pharmacy services throughout the post-acute 
care continuum.
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The National Health Insurance (NHI) Program in Taiwan is a mandatory govern-
ment-run social insurance system cover 99% of the population. Since its inception 
in 1995, NHI has been facing the challenges of rapid increase on health care costs, 
particularly in 1998; nominal growth rate of NHI costs reached 11.4% per year. So 
many strategies have been introduced in controlling costs and in improving qual-
ity of care, and the Second-Generation NHI was implemented in January 1, 2013. 
Among them the pharmaceutical benefits and expenditures strategies were the 
most important reforms. The drug cost of NHI was about 4.4 billion USD in 2012, 
nearly 25% of total health insurance expenditure, and drug cost per capita was 204 
USD. Over 18,000 drugs were listed in the Drug Price List, and average new drugs 
listed time was 144 days. The average growth rate on drug fees was 4.8% for recent 10 
years. Many strategies had been introduced to control drug costs, such that : (1) Drug 
Price List was revised continuously based on setting reference prices for the drugs 
with same ingredients .The price was adjusted 9 times from 2000 to 2011. (2) “Drug 
Expenditure Target” policy into practice in January 1, 2013. It control unreasonable 
drug fees rising, and make drug policy predictable to the pharmaceutical industrial 
in Taiwan. (3) other reform such as focused on efficient pharmaceutical benefits 
and payment systems, equity in pharmaceutical transactions, public participation 
and information transparency. However, these biggest reform are now high hopes 
